Keya Medical

Keya Medical is a commercial-stage AI diagnostics company focused on revolutionizing the assessment of coronary artery disease. Its core technology, DEEPVESSEL FFR, provides a non-invasive, AI-powered physiological analysis (FFRCT) from standard coronary CT angiography (CCTA) scans, helping clinicians determine if a patient requires invasive intervention. The company has achieved significant regulatory milestones, including FDA clearance (2022), CE Mark (2018), and NMPA approval in China (2020), and is benefiting from the establishment of a new Category I CPT code (75580) in the U.S. for FFRCT analysis. Keya Medical operates globally, with its software available in the USA, EMEA, China, and Singapore, positioning it at the intersection of the rapidly growing AI healthcare and cardiovascular diagnostics markets.

DEEPVESSEL AI platform for analyzing coronary CT angiography (CCTA) scans. It uses deep learning to create 3D coronary models and perform computational fluid dynamics simulations to derive non-invasive fractional flow reserve (FFRCT) and enable plaque analysis.

Keya Medical operates in the competitive AI-based FFRCT and cardiac CT analysis market. Its primary direct competitor is HeartFlow, the market pioneer. It also competes with other software solutions from large medtech OEMs (e.g., Siemens cFFR) and a growing field of AI startups focused on coronary plaque analysis (e.g., Cleerly). Differentiation is based on algorithm performance, workflow integration, pricing, and the breadth of the analytical suite.